Literature DB >> 28218257

Approvals in 2016: cost-benefit challenges of new anticancer agents.

Philip Savage1.   

Abstract

Mesh:

Substances:

Year:  2017        PMID: 28218257     DOI: 10.1038/nrclinonc.2017.12

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

Authors:  Bella Kaufman; Ronnie Shapira-Frommer; Rita K Schmutzler; M William Audeh; Michael Friedlander; Judith Balmaña; Gillian Mitchell; Georgeta Fried; Salomon M Stemmer; Ayala Hubert; Ora Rosengarten; Mariana Steiner; Niklas Loman; Karin Bowen; Anitra Fielding; Susan M Domchek
Journal:  J Clin Oncol       Date:  2014-11-03       Impact factor: 44.544

2.  Market spiral pricing of cancer drugs.

Authors:  Donald W Light; Hagop Kantarjian
Journal:  Cancer       Date:  2013-09-03       Impact factor: 6.860

3.  Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Authors:  Meletios A Dimopoulos; Albert Oriol; Hareth Nahi; Jesus San-Miguel; Nizar J Bahlis; Saad Z Usmani; Neil Rabin; Robert Z Orlowski; Mieczyslaw Komarnicki; Kenshi Suzuki; Torben Plesner; Sung-Soo Yoon; Dina Ben Yehuda; Paul G Richardson; Hartmut Goldschmidt; Donna Reece; Steen Lisby; Nushmia Z Khokhar; Lisa O'Rourke; Christopher Chiu; Xiang Qin; Mary Guckert; Tahamtan Ahmadi; Philippe Moreau
Journal:  N Engl J Med       Date:  2016-10-06       Impact factor: 91.245

4.  Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.

Authors:  Stephan Stilgenbauer; Barbara Eichhorst; Johannes Schetelig; Steven Coutre; John F Seymour; Talha Munir; Soham D Puvvada; Clemens-Martin Wendtner; Andrew W Roberts; Wojciech Jurczak; Stephen P Mulligan; Sebastian Böttcher; Mehrdad Mobasher; Ming Zhu; Monali Desai; Brenda Chyla; Maria Verdugo; Sari Heitner Enschede; Elisa Cerri; Rod Humerickhouse; Gary Gordon; Michael Hallek; William G Wierda
Journal:  Lancet Oncol       Date:  2016-05-10       Impact factor: 41.316

5.  Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

Authors:  Antonio Palumbo; Asher Chanan-Khan; Katja Weisel; Ajay K Nooka; Tamas Masszi; Meral Beksac; Ivan Spicka; Vania Hungria; Markus Munder; Maria V Mateos; Tomer M Mark; Ming Qi; Jordan Schecter; Himal Amin; Xiang Qin; William Deraedt; Tahamtan Ahmadi; Andrew Spencer; Pieter Sonneveld
Journal:  N Engl J Med       Date:  2016-08-25       Impact factor: 91.245

6.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

Authors:  Jonathan E Rosenberg; Jean Hoffman-Censits; Tom Powles; Michiel S van der Heijden; Arjun V Balar; Andrea Necchi; Nancy Dawson; Peter H O'Donnell; Ani Balmanoukian; Yohann Loriot; Sandy Srinivas; Margitta M Retz; Petros Grivas; Richard W Joseph; Matthew D Galsky; Mark T Fleming; Daniel P Petrylak; Jose Luis Perez-Gracia; Howard A Burris; Daniel Castellano; Christina Canil; Joaquim Bellmunt; Dean Bajorin; Dorothee Nickles; Richard Bourgon; Garrett M Frampton; Na Cui; Sanjeev Mariathasan; Oyewale Abidoye; Gregg D Fine; Robert Dreicer
Journal:  Lancet       Date:  2016-03-04       Impact factor: 79.321

7.  High cancer drug prices in the United States: reasons and proposed solutions.

Authors:  Hagop Kantarjian; David Steensma; Judit Rius Sanjuan; Adam Elshaug; Donald Light
Journal:  J Oncol Pract       Date:  2014-05-06       Impact factor: 3.840

8.  Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.

Authors:  William D Tap; Robin L Jones; Brian A Van Tine; Bartosz Chmielowski; Anthony D Elias; Douglas Adkins; Mark Agulnik; Matthew M Cooney; Michael B Livingston; Gregory Pennock; Meera R Hameed; Gaurav D Shah; Amy Qin; Ashwin Shahir; Damien M Cronier; Robert Ilaria; Ilaria Conti; Jan Cosaert; Gary K Schwartz
Journal:  Lancet       Date:  2016-06-09       Impact factor: 79.321

9.  Development and economic trends in cancer therapeutic drugs: a 5-year update 2010-2014.

Authors:  P Savage; S Mahmoud
Journal:  Br J Cancer       Date:  2015-03-17       Impact factor: 7.640

  9 in total
  3 in total

1.  BRCA1 and BRCA2 mutations and treatment strategies for breast cancer.

Authors:  Inês Godet; Daniele M Gilkes
Journal:  Integr Cancer Sci Ther       Date:  2017-02-27

Review 2.  Trends in Clinical Benefits and Costs of Novel Therapeutics in AML: at What Price Does Progress Come?

Authors:  Jennifer E Vaughn; Veena Shankaran; Roland B Walter
Journal:  Curr Hematol Malig Rep       Date:  2019-06       Impact factor: 3.952

3.  Atezolizumab plus platinum-based chemotherapy as first-line therapy for metastatic urothelial cancer: A cost-effectiveness analysis.

Authors:  Xiaoyan Liu; Yitian Lang; Qingqing Chai; Yan Lin; Yahui Liao; Yizhun Zhu
Journal:  Front Pharmacol       Date:  2022-08-22       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.